Gregory Sawicki, MD, MPH
Director, Cystic Fibrosis Center; Director, Safety and Quality Improvement
Associate Professor of Pediatrics, Harvard Medical School
Image
Email
Email Me
NPI
1295773588
Gregory Sawicki, MD, MPH
Director, Cystic Fibrosis Center; Director, Safety and Quality Improvement
Associate Professor of Pediatrics, Harvard Medical School
Medical Services
Languages
English
Education
Undergraduate School
Biochemical Sciences
Harvard College
1997
Cambridge
MA
Medical School
Harvard Medical School
2001
Cambridge
MA
Internship
Pediatrics
Boston Children's Hospital
2002
Boston
MA
Residency
Pediatrics Boston Combined Residency Program (BCRP)
Boston
MA
Fellowship
Pediatric Pulmonology Boston Children's Hospital
2007
Boston
MA
Graduate School
Harvard School of Public Health
2007
Boston
MA
Certifications
American Board of Pediatrics (Pulmonology)
Professional History
Dr. Sawicki received his MD from Harvard Medical School in 2001. He completed residency in Boston Combined Residency Program in Pediatrics in 2004, followed by fellowship in Pediatric Pulmonology at Boston Children’s Hospital (2004-2007). He also completed the Harvard Pediatric Health Services Research Fellowship in 2007, receiving an MPH in Clinical Effectiveness at the Harvard School of Public Health. Dr. Sawicki is currently the Director of the Cystic Fibrosis Center at Boston Children’s Hospital. Dr. Sawicki has a particular interest in addressing health outcomes and disease self-management for children, adolescents, and young adults with chronic respiratory diseases including cystic fibrosis and asthma.
Dr. Sawicki serves as an expert for the Department of Pulmonary Medicine for Boston Children's Hospital Precision Medicine Service. For more information about the Precision Medicine Service please visit bostonchildrens.org/precisionmed.
Publications
The effects of series elastic stiffness and cutaneous sensitivity on leg muscle reflex responses to unanticipated slips during walking. View Abstract
Cystic Fibrosis Learning Network Telehealth Innovation Lab During the COVID-19 Pandemic: Impact on Access to Care, Outcomes, and a New CF Care Model. View Abstract
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Extension Study. View Abstract
The Frequency and Potential Implications of HFE Genetic Variants in Children With Cystic Fibrosis. View Abstract
Predictive control of musculotendon loads across fast and slow-twitch muscles in a simulated system with parallel actuation. View Abstract
Acceptability of Telehealth Post-Pandemic Among Clinicians Across the United States Caring for People With Cystic Fibrosis. View Abstract
Male sexual and reproductive health in cystic fibrosis: A concept mapping study. View Abstract
Innovations in Evaluating Ambulatory Costs of Cystic Fibrosis Care: A Comparative Study Across Multidisciplinary Care Centers in Ireland and the United States. View Abstract
Electromyography-Informed Estimates of Joint Contact Forces Within the Lower Back and Knee Joints During a Diverse Set of Industry-Relevant Manual Lifting Tasks. View Abstract
"It's Like You're Feeding Your Child Twice": Barriers and Facilitators to Human Milk Feeding Children With Cystic Fibrosis. View Abstract
Center of mass states render multijoint torques throughout standing balance recovery. View Abstract
What does it mean to be "healthy" when taking elexacaftor/tezacaftor/ivacaftor (ETI)? A qualitative study. View Abstract
Qualitative understanding of experiences of people with cystic fibrosis in a treatment discontinuation trial: The QUEST study. View Abstract
Reduced Achilles tendon stiffness in aging associates with higher metabolic cost of walking. View Abstract
Plasma Microbial Cell-Free DNA Metagenomic Next-Generation Sequencing in People With Cystic Fibrosis. View Abstract
Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis. View Abstract
Factors associated with prescription of elexacaftor/tezacaftor/ivacaftor among people with cystic fibrosis aged 12 years or older with at least one F508del allele. View Abstract
Safety and tolerability of a low glycemic load dietary intervention in adults with cystic fibrosis: a pilot study. View Abstract
Self-reported chronic therapy use after 24-weeks of follow-up by participants who completed the simplify randomized, controlled trial. View Abstract
Overview and Updates in Pediatric Pulmonary Medicine. View Abstract
Center of mass states render multi-joint torques throughout standing balance recovery. View Abstract
Development and preliminary validation of the personalized cystic fibrosis medication questionnaire (PCF-MQ). View Abstract
Cross-Cutting mHealth Behavior Change Techniques to Support Treatment Adherence and Self-Management of Complex Medical Conditions: Systematic Review. View Abstract
Advances in Care and Outcomes for Children with Cystic Fibrosis. View Abstract
The effects of plantarflexor weakness and reduced tendon stiffness with aging on gait stability. View Abstract
A Data-Driven Approach to Estimate Human Center of Mass State During Perturbed Locomotion Using Simulated Wearable Sensors. View Abstract
Dynamic Duo: Design and Validation of an Autonomous Frontal and Sagittal Actuating Hip Exoskeleton for Balance Modulation During Perturbed Locomotion. View Abstract
An emotional journey: caregiver experiences with gastrostomy tube decision-making for children with cystic fibrosis. View Abstract
Continuous glucose monitoring and advanced glycation endproducts for prediction of clinical outcomes and development of cystic fibrosis-related diabetes in adults with CF. View Abstract
Habitually wearing high heels may improve user walking economy in any footwear. View Abstract
Safety and Pharmacokinetics Following Oral or Intravenous Lefamulin in Adults With Cystic Fibrosis. View Abstract
Randomized Trial of the Insulin-Only iLet Bionic Pancreas for the Treatment of Cystic Fibrosis- Related Diabetes. View Abstract
Reduced Achilles tendon stiffness in aging persists at matched activations and associates with higher metabolic cost of walking. View Abstract
Clinician perspectives and practices related to sexual and reproductive care provision for males with cystic fibrosis. View Abstract
Simulations suggest walking with reduced propulsive force would not mitigate the energetic consequences of lower tendon stiffness. View Abstract
Attenuation of muscle spindle firing with artificially increased series compliance during stretch of relaxed muscle. View Abstract
Predictive Control of Peak Achilles Tendon Force in a Simulated System of the Human Ankle Joint with a Parallel Artificial Actuator During Hopping. View Abstract
American Society of Biomechanics Journal of Biomechanics Award 2021: Exploring the Functional Boundaries and Metabolic Consequences of Triceps Surae Force-Length Relations during Walking. View Abstract
Attenuation of muscle spindle firing with artificially increased series compliance during stretch of relaxed muscle. View Abstract
Partners in research: The success with therapies research consortium and the CF community unite to improve self-management. View Abstract
The influence of induced gait asymmetry on joint reaction forces. View Abstract
Perturbing the muscle work loop paradigm to unravel the neuromechanics of unsteady locomotion. View Abstract
High deductible insurance plans impart economic burden for people with cystic fibrosis. View Abstract
How many billions is enough? Prioritizing profits over patients with cystic fibrosis. View Abstract
Long-term tezacaftor/ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-CFTR mutation: 96-week, open-label extension of the EXTEND trial. View Abstract
EFFECT OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR ON ANNUAL RATE OF LUNG FUNCTION DECLINE IN PEOPLE WITH CYSTIC FIBROSIS. View Abstract
Clinician perspectives on assessing for disordered eating and body image disturbance in adolescents and young adults with cystic fibrosis. View Abstract
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. View Abstract
Rate of Lung Function Decline in People with Cystic Fibrosis Having a Residual Function Gene Mutation. View Abstract
Sexual and reproductive health experiences and care of adult women with cystic fibrosis. View Abstract
Real-world feasibility of short-term, unsupervised home spirometry in CF. View Abstract
Eating disorders in adolescents and young adults with cystic fibrosis. View Abstract
Author Reply to: Empowering Without Misinforming Adolescents and Young Adults with Cystic Fibrosis. Comment on "Perceptions of Social Media Use to Augment Health Care Among Adolescents and Young Adults With Cystic Fibrosis: Survey Study". View Abstract
Continuous Glucose Monitoring and HbA1c in Cystic Fibrosis: Clinical Correlations and Implications for CFRD Diagnosis. View Abstract
Understanding the Intersection between Gender Transition and Health Outcomes in Cystic Fibrosis. View Abstract
A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children = 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant. View Abstract
Men's sexual and reproductive health in cystic fibrosis in the era of highly effective modulator therapies-A qualitative study. View Abstract
Engaging Stakeholders in the Development of a Reproductive Goals Decision AID for Women with Cystic Fibrosis. View Abstract
The Relationship between Body Composition, Dietary Intake, Physical Activity, and Pulmonary Status in Adolescents and Adults with Cystic Fibrosis. View Abstract
Exploring provider attitudes and perspectives related to men's health in cystic fibrosis. View Abstract
Trajectories of the Transition Readiness Assessment Questionnaire Among Youth With Inflammatory Bowel Disease. View Abstract
Financial impacts of the COVID-19 pandemic on cystic fibrosis care: lessons for the future. View Abstract
Patient and family experience of telehealth care delivery as part of the CF chronic care model early in the COVID-19 pandemic. View Abstract
Remote monitoring in telehealth care delivery across the U.S. cystic fibrosis care network. View Abstract
Evaluating barriers to and promoters of telehealth during the COVID-19 pandemic at U.S. cystic fibrosis programs. View Abstract
Prevalence, variability, and predictors of sinus surgery in pediatric patients with cystic fibrosis. View Abstract
The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis. View Abstract
Favorable Clinician Acceptability of Telehealth as Part of the Cystic Fibrosis Care Model during the COVID-19 Pandemic. View Abstract
Perceptions of Social Media Use to Augment Health Care Among Adolescents and Young Adults With Cystic Fibrosis: Survey Study. View Abstract
Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design. View Abstract
Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation. View Abstract
The Effects of Ivacaftor on Bone Density and Microarchitecture in Children and Adults with Cystic Fibrosis. View Abstract
Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial. View Abstract
Rapid Implementation of Telehealth Services in a Pediatric Pulmonary Clinic During COVID-19. View Abstract
An evaluation of healthcare utilization and clinical charges in children and adults with cystic fibrosis. View Abstract
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. View Abstract
Improvement of Pulmonary Function in Cystic Fibrosis Patients following Endoscopic Sinus Surgery. View Abstract
Tribulations and (clinical) trials in cystic fibrosis. View Abstract
Transition Readiness Not Associated With Measures of Health in Youth With IBD. View Abstract
Men's health in the modern era of cystic fibrosis. View Abstract
Monogenic Diabetes in a Child with Cystic Fibrosis: A Case Report and Review of the Literature. View Abstract
Decreased survival in cystic fibrosis patients with a positive screen for depression. View Abstract
Survey of patients with cystic fibrosis and caregivers decisions regarding CFTR modulators. View Abstract
Caregiver Burden Due to Pulmonary Exacerbations in Patients with Cystic Fibrosis. View Abstract
Male gender and unemployment are associated with lower levels of perceived social support in adults with cystic fibrosis. View Abstract
Medical Deferred Action - Living on Borrowed Time. View Abstract
Predictors of pulmonary exacerbation treatment in cystic fibrosis. View Abstract
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11?years with cystic fibrosis. View Abstract
Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries. View Abstract
Chronic rhino-sinusitis treatment in children with cystic fibrosis: A cross-sectional survey of pediatric pulmonologists and otolaryngologists. View Abstract
An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5?years (KLIMB). View Abstract
Developing Sexual and Reproductive Health Educational Resources for Young Women with Cystic Fibrosis: A Structured Approach to Stakeholder Engagement. View Abstract
Linkage of the CF foundation patient registry with the pediatric health information system database. View Abstract
Interprofessional provider educational needs and preferences regarding the provision of sexual and reproductive health care in cystic fibrosis. View Abstract
Social support is associated with fewer reported symptoms and decreased treatment burden in adults with cystic fibrosis. View Abstract
Cystic Fibrosis And Ivacaftor Use: The Authors Reply. View Abstract
Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. View Abstract
Healthcare expenditures for privately insured US patients with cystic fibrosis, 2010-2016. View Abstract
Disparities in Mortality of Hispanic Patients with Cystic Fibrosis in the United States. A National and Regional Cohort Study. View Abstract
Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: Current practices and research priorities. View Abstract
Rate and predictors of prescription of lumacaftor - Ivacaftor in the 18?months following approval in the United States. View Abstract
Sexual and Reproductive Health of Young Women With Cystic Fibrosis: A Concept Mapping Study. View Abstract
The burden of cystic fibrosis in the Medicaid population. View Abstract
Overcoming psychosocial challenges in cystic fibrosis: Promoting resilience. View Abstract
Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. View Abstract
Precision Medicine In Action: The Impact Of Ivacaftor On Cystic Fibrosis-Related Hospitalizations. View Abstract
Perspectives of adolescent girls with cystic fibrosis and parents on disease-specific sexual and reproductive health education. View Abstract
Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis. View Abstract
Cystic fibrosis patient registries: A valuable source for clinical research. View Abstract
Outcome evaluation of a pharmacy-based therapy management program for patients with cystic fibrosis. View Abstract
Risk Factors for Gaps in Care during Transfer from Pediatric to Adult Cystic Fibrosis Programs in the United States. View Abstract
Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis. View Abstract
Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation. View Abstract
Sexual and reproductive health care utilization and preferences reported by young women with cystic fibrosis. View Abstract
Mental Health Screening of Medically-Admitted Patients With Cystic Fibrosis. View Abstract
Incident Stenotrophomonas maltophilia infection and lung function decline in cystic fibrosis. View Abstract
Early Lung Function Decline in Cystic Fibrosis. Can Registry Data Explain Divergent Phenotypes? View Abstract
Pediatric lung transplantation and end of life care in cystic fibrosis: Barriers and successful strategies. View Abstract
Sexual and reproductive health behaviors and experiences reported by young women with cystic fibrosis. View Abstract
Preparation for Transition to Adult Care Among Medicaid-Insured Adolescents. View Abstract
Patients with Cystic Fibrosis and a G551D or Homozygous F508del Mutation: Similar Lung Function Decline. View Abstract
Impact of an Individual Mandate and Other Health Reforms on Dependent Coverage for Adolescents and Young Adults. View Abstract
Utilization of a patient-centered asthma passport tool in a subspecialty clinic. View Abstract
Microbiology of the Upper and Lower Airways in Pediatric Cystic Fibrosis Patients. View Abstract
Correlation of Transient Elastography With Severity of Cystic Fibrosis-related Liver Disease. View Abstract
The CF-CARES primary palliative care model: A CF-specific structured assessment of symptoms, distress, and coping. View Abstract
Adherence and Recursive Perception Among Young Adults with Cystic Fibrosis. View Abstract
Counterpoint: Too little care or too little collaboration: Approaches to treatment refusal in CF. View Abstract
Provider Attitudes and Practices toward Sexual and Reproductive Health Care for Young Women with Cystic Fibrosis. View Abstract
Reply: Combining Clinical Trial and Patient Registry Data in Cystic Fibrosis: Who Should Be Compared? View Abstract
Obesity and Airway Dysanapsis in Children with and without Asthma. View Abstract
Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. View Abstract
Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder. View Abstract
Strategies to optimize treatment adherence in adolescent patients with cystic fibrosis. View Abstract
Transition and transfer of childhood cancer survivors to adult care: A national survey of pediatric oncologists. View Abstract
Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis. View Abstract
Young adults with cystic fibrosis have altered trabecular microstructure by ITS-based morphological analysis. View Abstract
Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. View Abstract
Risk Factors for Hearing Loss in Patients with Cystic Fibrosis. View Abstract
CF RISE: Implementing a Clinic-Based Transition Program. View Abstract
Tackling the increasing complexity of CF care. View Abstract
Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. View Abstract
Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years. View Abstract
Development and Validation of the Adolescent Assessment of Preparation for Transition: A Novel Patient Experience Measure. View Abstract
Rate of Uptake of Ivacaftor Use after U.S. Food and Drug Administration Approval among Patients Enrolled in the U.S. Cystic Fibrosis Foundation Patient Registry. View Abstract
A randomized controlled trial of vitamin D replacement strategies in pediatric CF patients. View Abstract
Self-Management and Transition Readiness Assessment: Concurrent, Predictive and Discriminant Validation of the STARx Questionnaire. View Abstract
Predictors of timing of transfer from pediatric- to adult-focused primary care. View Abstract
Similar performance of Brasfield and Wisconsin scoring systems in young children with cystic fibrosis. View Abstract
Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients. View Abstract
Development and evaluation of a palliative care curriculum for cystic fibrosis healthcare providers. View Abstract
Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site. View Abstract
Ready, set, stop: mismatch between self-care beliefs, transition readiness skills, and transition planning among adolescents, young adults, and parents. View Abstract
The Transition Readiness Assessment Questionnaire (TRAQ): its factor structure, reliability, and validity. View Abstract
Compromised bone microarchitecture and estimated bone strength in young adults with cystic fibrosis. View Abstract
Inter-hospital variation in the frequency of sinus surgery in children with cystic fibrosis. View Abstract
Motivating adherence among adolescents with cystic fibrosis: youth and parent perspectives. View Abstract
Transition care: future directions in education, health policy, and outcomes research. View Abstract
Vitamin D status in children with cystic fibrosis. Associations with inflammation and bacterial colonization. View Abstract
Transition and transfer of adolescents and young adults with pediatric onset chronic disease: the patient and parent perspective. View Abstract
Brasfield and Wisconsin scoring systems have equal value as outcome assessment tools of cystic fibrosis lung disease. View Abstract
Longitudinal trends in health-related quality of life in adults with cystic fibrosis. View Abstract
Claim-based analyses of inhaled corticosteroid refill rates for asthma: who's kidding whom? View Abstract
Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes. View Abstract
A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care. View Abstract
Referral patterns and perceived barriers to adult congenital heart disease care: results of a survey of U.S. pediatric cardiologists. View Abstract
Managing treatment complexity in cystic fibrosis: challenges and opportunities. View Abstract
Erratum to: Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national, US sample. View Abstract
The impact of reflux burden on Pseudomonas positivity in children with cystic fibrosis. View Abstract
Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample. View Abstract
Physician practices for communicating with patients with cystic fibrosis about the use of noninvasive and invasive mechanical ventilation. View Abstract
Assessment of current strategies for weaning premature infants from supplemental oxygen in the outpatient setting. View Abstract
Receipt of health care transition counseling in the national survey of adult transition and health. View Abstract
Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. View Abstract
Tree nut allergy, egg allergy, and asthma in children. View Abstract
Longitudinal assessment of health-related quality of life in an observational cohort of patients with cystic fibrosis. View Abstract
Employment experiences among adolescents and young adults with cystic fibrosis. View Abstract
Associations between illness perceptions and health-related quality of life in adults with cystic fibrosis. View Abstract
Uncontrolled asthma in a commercially insured population from 2002 to 2007: trends, predictors, and costs. View Abstract
Cystic fibrosis and transition to adult medical care. View Abstract
Asthma care quality for children with minority-serving providers. View Abstract
Patterns of inhaled corticosteroid use and asthma control in the Childhood Asthma Management Program Continuation Study. View Abstract
Measuring the transition readiness of youth with special healthcare needs: validation of the TRAQ--Transition Readiness Assessment Questionnaire. View Abstract
Travel patterns to school among children with asthma. View Abstract
The impact of MRSA on lung function in patients with cystic fibrosis. View Abstract
The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis. View Abstract
High treatment burden in adults with cystic fibrosis: challenges to disease self-management. View Abstract
Advance care planning in adults with cystic fibrosis. View Abstract
Necrotising pneumonia is an increasingly detected complication of pneumonia in children. View Abstract
Self-reported physical and psychological symptom burden in adults with cystic fibrosis. View Abstract
Periodic use of inhaled steroids in children with mild persistent asthma: what are pediatricians recommending? View Abstract
Bronchoscopy findings in children and young adults with tracheostomy due to congenital anomalies and neurological impairment. View Abstract
Mucoepidermoid carcinoma of bronchus in a pediatric patient: (18)F-FDG PET findings. View Abstract
Self-reported involvement of family members in the care of adults with CF. View Abstract
Adults with cystic fibrosis report important and unmet needs for disease information. View Abstract
Phenotypic and cytokine analysis of human peripheral blood gamma delta T cells expressing NK cell receptors. View Abstract